Genmab — Juli 2017
-
-
299
-
fra JNJ's hjemmeside, inkl. tallene http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=1033438
-
Strong growth in new products include DARZALEX
(daratumumab), for the treatment of patients with multiple myeloma -
jeg forstår ikke helt US actual tallet ifht recepttallene. Med en flad udvikling i juni burdre US omsætningen have været over usd 230m
-
Hvis man regner med 17,25% stigning ligeledes i de næste 2 kvartaler. Så kommer Q3 på 350, Q4 på 410 og hele året på 1314.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind